Remission rate 34 pct for Seattle Genetics drug
(Reuters)
Unusual Little Blurbs
Reuters - A pivotal trial of Seattle Genetics' experimental cancer-targeting antibody for patients with Hodgkin's lymphoma found that more than a third of them achieved complete remission of their cancer.
Source: Yahoo! News: Biotechnology News